Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
Xun Wang, Xiaoyu Zhao, Jieyu Song, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 477-481
Open Access | Times Cited: 129

Showing 26-50 of 129 citing articles:

Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
Julien Favresse, Constant Gillot, Jean‐Louis Bayart, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 37
The Association between Risk Perception and Hesitancy toward the Booster Dose of COVID-19 Vaccine among People Aged 60 Years and Older in China
Chenyuan Qin, Wenxin Yan, Liyuan Tao, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1112-1112
Open Access | Times Cited: 36
A comprehensive review on Covid-19 Omicron (B.1.1.529) variant
R. Manjunath, Santosh L. Gaonkar, Ebraheem Abdu Musad Saleh, et al.
Saudi Journal of Biological Sciences (2022) Vol. 29, Iss. 9, pp. 103372-103372
Open Access | Times Cited: 33
Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review
Zhonghao Chen, Ying Zhang, Meng Wang, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 12, pp. 4629-4641
Open Access | Times Cited: 33
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
Yuemiao Zhang, Xupu Ma, Guanghong Yan, et al.
EClinicalMedicine (2022) Vol. 54, pp. 101680-101680
Open Access | Times Cited: 30
A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2
Shanhong Mao, Shiyou Li, Yuxin Zhang, et al.
Nano Today (2022) Vol. 48, pp. 101730-101730
Open Access | Times Cited: 30
Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination 1
Hongyu Wang, Quanlin Xue, Haocheng Zhang, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 21
Continued evasion of neutralizing antibody response by Omicron XBB.1.16
Julia N. Faraone, Panke Qu, Yi-Min Zheng, et al.
Cell Reports (2023) Vol. 42, Iss. 10, pp. 113193-113193
Open Access | Times Cited: 20
The regulation of lncRNAs and miRNAs in SARS-CoV-2 infection
Yuhao Lin, Qiqi Sun, Bao Zhang, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 17
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial
Nawal Al Kaabi, Yun Yang, Jing Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 28
COVID-19 booster dose induces robust antibody response in pregnant, lactating, and nonpregnant women
Caroline Atyeo, Lydia L. Shook, Nadege Nziza, et al.
American Journal of Obstetrics and Gynecology (2022) Vol. 228, Iss. 1, pp. 68.e1-68.e12
Open Access | Times Cited: 27
The rapid emergence of multiple sublineages of Omicron (B.1.1.529) variant: Dynamic profiling via molecular phylogenetics and mutational landscape studies
Chiranjib Chakraborty, Manojit Bhattacharya, Ashish Ranjan Sharma, et al.
Journal of Infection and Public Health (2022) Vol. 15, Iss. 11, pp. 1234-1258
Open Access | Times Cited: 27
Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant
Naru Zhang, Qianting Ji, Zezhong Liu, et al.
Viruses (2022) Vol. 14, Iss. 3, pp. 501-501
Open Access | Times Cited: 25
Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
Chao Wang, Linyi Chen, Qing‐Bin Lu, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 920-920
Open Access | Times Cited: 25
Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
Ailan Xu, Bixia Hong, Fuxing Lou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 25
Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-lineages
Jingwen Ai, Xun Wang, Xinyi He, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 23
The spread of the omicron variant: Identification of knowledge gaps, virus diffusion modelling, and future research needs
Uttpal Anand, Tarun Pal, Alessandra Zanoletti, et al.
Environmental Research (2023) Vol. 225, pp. 115612-115612
Open Access | Times Cited: 14
Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus
Jacob A. Dillard, Sharon Taft-Benz, Audrey C. Knight, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
Irene González‐Domínguez, José Luis Martínez, Stefan Slamanig, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 22
Predicting unseen antibodies’ neutralizability via adaptive graph neural networks
Jie Zhang, Yishan Du, Pengfei Zhou, et al.
Nature Machine Intelligence (2022) Vol. 4, Iss. 11, pp. 964-976
Open Access | Times Cited: 21
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial
Shengli Xia, Kai Duan, Yuntao Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 20
COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
Dorota Zarębska‐Michaluk, Chenlin Hu, Michał Brzdęk, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1223-1223
Open Access | Times Cited: 20
COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness
Yousra Kherabi, Odile Launay, Liêm Binh Luong Nguyen
Viruses (2022) Vol. 14, Iss. 10, pp. 2086-2086
Open Access | Times Cited: 20
Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
Xuejun Wang, Lin Yao, Hong‐Yun Zhang, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 20
Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity
James A. Williams, Marco Biancucci, Laura N. Lessen, et al.
Science Advances (2023) Vol. 9, Iss. 23
Open Access | Times Cited: 13

Scroll to top